Myelodysplastic syndrome Program in Pharmaceutical Benefits Scheme (PBS) 012-18051125
Expand allThis document outlines details of PBS-subsidised azacitidine, decitabine+cedazuridine and lenalidomide for patients with myelodysplastic syndrome (MDS).
Myelodysplastic syndrome and listing dates
Myelodysplastic syndromes (MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells.
Listing dates are:
- azacitidine - 1 February 2011
- lenalidomide - 1 October 2013
- decitabine+cedazuridine - 1 October 2022
See Written Authority Required for Drugs for more details.
Enquiries
- Transfer enquiries about prescription arrangements for:
- azacitidine and lenalidomide to the PBS Complex Drugs Programs and choose the option relevant to the condition treated
- decitabine+cedazuridine to PBS authority approvals
The Resources page contains:
- application forms
- contact details
- restriction and item codes
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing and National Demand Allocation (PaNDA)